Guardant Health (GH) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $19.54B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Helmy Eltoukhy |
| IPO Date | 2018-10-04 | CAGR | 50.19% |
| Employees | 2,506 | Website | guardanthealth.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $16.58B | P/E | -57.1 | Forward P/E | -340.1 | PEG | — |
| P/S | 6635.24 | P/B | -39186.37 | P/CF | -40451.18 | P/FCF | -31875.93 |
| Sales | $1.08B | Sales 1Y | 39.56% | Sales 3Y | 124.04% | Sales 5Y | 262.63% |
| EPS | $-2.58 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 7.25% | EPS QoQ | -15% | Sales QoQ Avg | 10.41% | EPS QoQ Avg | 4.13% |
| Gross Margin | 64.9% | Operating Margin | -41.43% | Profit Margin | -40.1% | ROCE | -27.57% |
| ROA | -23% | ROE | 184% | Altman Z Score | 3.82 | Piotroski Score | 4 |
| Current Ratio | 4.68 | Quick Ratio | 4.39 | Cash Ratio | 3.39 | Op. CF Ratio | -0.22 |
| Debt/Equity | -9.26 | Debt/Assets | 0.88 | Lt Debt/Equity | -9.26 | Lt Debt/Cap. | 1.12 |
| Intrst Cov. | -100.51 | Inventory Turnover | 4.52 | Asset Turnover | 0.56 | Receivables Turnover | 7.86 |
| Enterprise Value | $16.58B | P/E Ratio | -57.1 |
| Forward P/E | -340.1 | PEG Ratio | — |
| P/S Ratio | 6635.24 | P/B Ratio | -39186.37 |
| P/CF Ratio | -40451.18 | P/FCF Ratio | -31875.93 |
| EPS | $-2.58 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 39.56% | Gross Margin | 0.65% |
| Operating Margin | -0.41% | Profit Margin | -0.4% |
| ROE | 1.84% | ROA | -0.23% |
| ROCE | -0.28% | Current Ratio | 4.68 |
| Quick Ratio | 4.39 | Cash Ratio | 3.39 |
| Debt/Equity | -9.26 | Interest Coverage | -100.51 |
| Altman Z Score | 3.82 | Piotroski Score | 4 |
Guardant Health (GH) valuation & financials
Guardant Health (GH) has a market capitalization of $19.54B and trades at a price-to-earnings ratio of -57.1. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Guardant Health's revenue grew +39.6% over the last year.
Guardant Health's next earnings report is scheduled for July 30, 2026 after market close; analysts estimate EPS of $-0.41.
Guardant Health (GH) — frequently asked questions
When does Guardant Health (GH) report earnings next?
Guardant Health is expected to report earnings on July 30, 2026 after market close. Analysts estimate EPS of $-0.41.
What is Guardant Health's market cap?
Guardant Health (GH) has a market capitalization of $19.54B.
What is GH's P/E ratio?
Guardant Health trades at a price-to-earnings ratio of -57.1, with trailing twelve-month EPS of $-2.58.
How fast is Guardant Health growing?
Guardant Health's revenue grew +39.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)